May 2009
·
10 Reads
Nouvelles Dermatologiques
Imiquimod and its structural analogs (imidazoquinolines) act as artificial ligands for innate immunity receptors (Toll-like receptors or TLRs). Activation of TLRs initiate signalling pathways leading to the release of cytokines. These cytokines have inflammatory, antiinfectious, antitumour effects and promote cooperation between innate and adaptative immunity. Imiquimod only is a registered drug in France, with indication for condylomas, superficial basal cell carcinomas and actinic keratosis. Many other indications are under trial in the field of skin infections and skin cancers.